Pfizer's total revenue 2006-2020

Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2020, the company's total revenue was about 42 billion U.S. dollars. This is a significant decrease compared to the year before and, of course, a consequence of the spin-off of the company's Upjohn business during that year.

Pfizer’s global positioning

Pfizer’s products are available in over 125 countries worldwide and as of 2020 the company had 170 research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the top 5 pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few.

Pfizer’s top products

Pfizer has several products that are quite popular. In 2020, drugs in the Prevnar family, followed by Ibrance, were their top products based on revenue. However, Pfizer has several other drugs that are also well known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.